424 related articles for article (PubMed ID: 26344417)
21. Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma.
Pérez-Martínez FC; Alonso V; Sarasa JL; Manzarbeitia F; Vela-Navarrete R; Calahorra FJ; Esbrit P
Histol Histopathol; 2008 Jun; 23(6):709-15. PubMed ID: 18366009
[TBL] [Abstract][Full Text] [Related]
22. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
23. Prediction of biochemical recurrence after robot-assisted radical prostatectomy: analysis of 784 Japanese patients.
Hashimoto T; Yoshioka K; Nagao G; Nakagami Y; Ohno Y; Horiguchi Y; Namiki K; Nakashima J; Tachibana M
Int J Urol; 2015 Feb; 22(2):188-93. PubMed ID: 25339062
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
25. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.
Kimura T; Furusato B; Miki J; Yamamoto T; Hayashi N; Takahashi H; Kamata Y; van Leenders GJ; Visakorpi T; Egawa S
Pathol Int; 2012 Nov; 62(11):742-8. PubMed ID: 23121605
[TBL] [Abstract][Full Text] [Related]
26. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
27. Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading.
Terracciano D; Bruzzese D; Ferro M; Mazzarella C; Di Lorenzo G; Altieri V; Mariano A; Macchia V; Di Carlo A
Prostate; 2012 Jan; 72(1):100-7. PubMed ID: 21520165
[TBL] [Abstract][Full Text] [Related]
28. Residual prostatic tumour in the surgical bed following radical prostatectomy in organ-confined prostate cancer: possible prognostic significance.
Valotto C; Falconieri G; Pizzolitto S; Cerruto MA; Brondani G; De Gobbi A; Zattoni F
Arch Ital Urol Androl; 2011 Jun; 83(2):78-82. PubMed ID: 21826879
[TBL] [Abstract][Full Text] [Related]
29. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
30. Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease.
Corcoran NM; Hovens CM; Metcalfe C; Hong MK; Pedersen J; Casey RG; Peters J; Harewood L; Goldenberg SL; Costello AJ; Gleave ME
BJU Int; 2012 Sep; 110(6):821-7. PubMed ID: 22257140
[TBL] [Abstract][Full Text] [Related]
31. Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options.
Janiczek M; Szylberg Ł; Antosik P; Kasperska A; Marszałek A
J Immunol Res; 2020; 2020():4910595. PubMed ID: 32537467
[TBL] [Abstract][Full Text] [Related]
32. TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy.
Raatikainen S; Aaltomaa S; Palvimo JJ; Kärjä V; Soini Y
Scand J Urol; 2015 Feb; 49(1):51-7. PubMed ID: 24779451
[TBL] [Abstract][Full Text] [Related]
33. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
Xu C; Jung M; Burkhardt M; Stephan C; Schnorr D; Loening S; Jung K; Dietel M; Kristiansen G
Prostate; 2005 Feb; 62(3):224-32. PubMed ID: 15389793
[TBL] [Abstract][Full Text] [Related]
34. Biochemical recurrence rates are similar for pT2-positive surgical margins and pT3a.
Leite KR; Hartmann C; Reis ST; Viana N; Dall'Oglio MF; Sant'Anna AC; Nesrallah A; Nesrallah L; Antunes AA; Camara-Lopes LH; Srougi M
Int Braz J Urol; 2014; 40(2):146-53. PubMed ID: 24856481
[TBL] [Abstract][Full Text] [Related]
35. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
Chen YB; Fine SW; Epstein JI
Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
[TBL] [Abstract][Full Text] [Related]
36. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
37. Adenocarcinoma on needle prostatic biopsies: does reactive stroma predicts biochemical recurrence in patients following radical prostatectomy?
Billis A; Meirelles L; Freitas LL; Polidoro AS; Fernandes HA; Padilha MM; Magna LA; Reis LO; Ferreira U
Int Braz J Urol; 2013; 39(3):320-7. PubMed ID: 23849565
[TBL] [Abstract][Full Text] [Related]
38. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
39. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
40. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
